Benzinga - by Benzinga Insights, Benzinga Staff Writer.
Disclosed on June 20, Sagar Lonial, Director at TG Therapeutics (NASDAQ:TGTX), executed a substantial insider sell as per the latest SEC filing.
What Happened: Lonial's recent Form 4 filing with the U.S. Securities and Exchange Commission on Thursday unveiled the sale of 25,933 shares of TG Therapeutics. The total transaction value is $432,888.
During Friday's morning session, TG Therapeutics shares up by 0.24%, currently priced at $17.02.
Discovering TG Therapeutics: A Closer Look TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
TG Therapeutics: Delving into Financials Revenue Growth: TG Therapeutics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 713.46%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Navigating Financial Profits:
- Gross Margin: The company maintains a high gross margin of 91.43%, indicating strong cost management and profitability compared to its peers.
- Earnings per Share (EPS): TG Therapeutics's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of -0.07.
Navigating Market Valuation:
- Price to Earnings (P/E) Ratio: The P/E ratio of 56.53 is lower than the industry average, implying a discounted valuation for TG Therapeutics's stock.
- Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 8.79, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 46.67, TG Therapeutics presents an attractive value opportunity.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Key in Investment Decisions Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
Deciphering Transaction Codes in Insider Filings When analyzing transactions, investors tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of TG Therapeutics's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.